QuantHealth, a Tel Aviv, Israel-based AI-powered clinical trial design company that simulates clinical trials, received a strategic investment from Accenture Ventures along with participation from a CRO firm and additional investors.
The new capital will enable the company to enhance its platform. This announcement extends QuantHealth’s recent $15M Series A funding round to $17M co-led by Bertelsmann Investments and Pitango HealthTech, with participation from existing investors Shoni Top Ventures and Nina Capital.
With proprietary AI technology trained on a massive dataset of 350 million patients, large biomedical knowledge-graphs, and clinical trial data, QuantHealth’s simulation platform can predict trial outcomes with 86 percent accuracy on the binary endpoint metric. It can test thousands of protocol variations and discover the optimal trial design for success, helping research and development (R&D) teams more accurately and rapidly develop and optimize trial protocols.
Led by Orr Inbar, co-founder and CEO, QuantHealth is already working with several global pharmaceutical companies to use its product in clinical trial design and development. The funding is also followed by QuantHealth’s latest product launch, Katina, which provides clinical researchers with an AI-guided workflow that simulates hundreds of thousands of potential trial protocol combinations of patient groups, treatment parameters and different endpoints, to maximize the trial success probability.
FinSMEs
08/01/2023